Mizuho Securities Maintains Nektar Therapeutics (NKTR) at Neutral Rating with $6 Price Target on Cost Restructuring, But Pipeline Remains a Concern
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Neutral rating and $6.00 price target on Nektar Therapeutics (NASDAQ: NKTR), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
